Výsledky vyhľadávania - "Gibson, C. Michael"

In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat? Autor Gibson, C Michael

Zistit podrobnosti o prístupe

Saphenous vein grafts in contemporary coronary artery bypass graft surgery Autor Caliskan, Etem, de Souza, Domingos Ramos, Böning, Andreas, Liakopoulos, Oliver J, Choi, Yeong-Hoon, Pepper, John, Gibson, C Michael, Perrault, Louis P, Wolf, Randall K, Kim, Ki-Bong, Emmert, Maximilian Y

“…Myocardial ischaemia resulting from obstructive coronary artery disease is a major cause of morbidity and mortality in the developed world. Coronary artery…”
Získať plný text

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Autor Connolly, Stuart J, Milling, Truman J, Eikelboom, John W, Gibson, C. Michael, Curnutte, John T, Gold, Alex, Bronson, Michele D, Lu, Genmin, Conley, Pamela B, Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T, Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Goodman, Shelly, Leeds, Janet, Wiens, Brian L, Siegal, Deborah M, Zotova, Elena, Meeks, Brandi, Nakamya, Juliet, Lim, W. Ting, Crowther, Mark

“…Andexanet alfa, a catalytically inactive decoy of factor Xa, successfully reversed the factor Xa inhibitory effects of rivaroxaban and apixaban in a small…”
Získať plný text

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI Autor Gibson, C. Michael, Mehran, Roxana, Bode, Christoph, Halperin, Jonathan, Verheugt, Freek W, Wildgoose, Peter, Birmingham, Mary, Ianus, Juliana, Burton, Paul, van Eickels, Martin, Korjian, Serge, Daaboul, Yazan, Lip, Gregory Y.H, Cohen, Marc, Husted, Steen, Peterson, Eric D, Fox, Keith A

“…This trial compared standard therapy (dual antiplatelet therapy plus a vitamin K antagonist) with two regimens containing rivaroxaban plus antiplatelet…”
Získať plný text

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk Autor Urban, Philip, Mehran, Roxana, Colleran, Roisin, Angiolillo, Dominick J, Byrne, Robert A, Capodanno, Davide, Cuisset, Thomas, Cutlip, Donald, Eerdmans, Pedro, Eikelboom, John, Farb, Andrew, Gibson, C Michael, Gregson, John, Haude, Michael, James, Stefan K, Kim, Hyo-Soo, Kimura, Takeshi, Konishi, Akihide, Laschinger, John, Leon, Martin B, Magee, P F Adrian, Mitsutake, Yoshiaki, Mylotte, Darren, Pocock, Stuart, Price, Matthew J, Rao, Sunil V, Spitzer, Ernest, Stockbridge, Norman, Valgimigli, Marco, Varenne, Olivier, Windhoevel, Ute, Yeh, Robert W, Krucoff, Mitchell W, Morice, Marie-Claude

“…Abstract Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of…”
Získať plný text

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS Autor Baber, Usman, Mehran, Roxana, Giustino, Gennaro, Cohen, David J, Henry, Timothy D, Sartori, Samantha, Ariti, Cono, Litherland, Claire, Dangas, George, Gibson, C Michael, Krucoff, Mitchell W, Moliterno, David J, Kirtane, Ajay J, Stone, Gregg W, Colombo, Antonio, Chieffo, Alaide, Kini, Annapoorna S, Witzenbichler, Bernhard, Weisz, Giora, Steg, Philippe Gabriel, Pocock, Stuart

“…Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the…”
Zistit podrobnosti o prístupe

Bleeding avoidance strategies in percutaneous coronary intervention Autor Capodanno, Davide, Bhatt, Deepak L, Gibson, C Michael, James, Stefan, Kimura, Takeshi, Mehran, Roxana, Rao, Sunil V, Steg, Philippe Gabriel, Urban, Philip, Valgimigli, Marco, Windecker, Stephan, Angiolillo, Dominick J

“…For many years, bleeding has been perceived as an unavoidable consequence of strategies aimed at reducing thrombotic complications in patients undergoing…”
Získať plný text

Ticagrelor with or without Aspirin in High-Risk Patients after PCI Autor Mehran, Roxana, Baber, Usman, Sharma, Samin K, Cohen, David J, Angiolillo, Dominick J, Briguori, Carlo, Cha, Jin Y, Collier, Timothy, Dangas, George, Dudek, Dariusz, Džavík, Vladimír, Escaned, Javier, Gil, Robert, Gurbel, Paul, Hamm, Christian W, Henry, Timothy, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell, Kunadian, Vijay, Marx, Steven O, Mehta, Shamir R, Moliterno, David, Ohman, E. Magnus, Oldroyd, Keith, Sardella, Gennaro, Sartori, Samantha, Shlofmitz, Richard, Steg, P. Gabriel, Weisz, Giora, Witzenbichler, Bernhard, Han, Ya-ling, Pocock, Stuart, Gibson, C. Michael

“…In this placebo-controlled trial, 7119 patients were randomly assigned at 3 months after PCI to either receive ticagrelor alone or continue dual therapy with…”
Získať plný text

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors Autor Connolly, Stuart J, Crowther, Mark, Eikelboom, John W, Gibson, C. Michael, Curnutte, John T, Lawrence, John H, Yue, Patrick, Bronson, Michele D, Lu, Genmin, Conley, Pamela B, Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T, Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M, Pallin, Daniel J, Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M, Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J

“…In a single-group trial, 352 patients with acute major bleeding while taking a factor Xa inhibitor were treated with andexanet. Andexanet markedly reduced…”
Získať plný text

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease Autor Lincoff, A. Michael, Nicholls, Stephen J, Riesmeyer, Jeffrey S, Barter, Philip J, Brewer, H. Bryan, Fox, Keith A.A, Gibson, C. Michael, Granger, Christopher, Menon, Venu, Montalescot, Gilles, Rader, Daniel, Tall, Alan R, McErlean, Ellen, Wolski, Kathy, Ruotolo, Giacomo, Vangerow, Burkhard, Weerakkody, Govinda, Goodman, Shaun G, Conde, Diego, McGuire, Darren K, Nicolau, Jose C, Leiva-Pons, Jose L, Pesant, Yves, Li, Weimin, Kandath, David, Kouz, Simon, Tahirkheli, Naeem, Mason, Denise, Nissen, Steven E

“…In a randomized trial involving patients with high-risk vascular disease, the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on…”
Získať plný text

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study Autor Mehran, Roxana, Baber, Usman, Steg, Philippe Gabriel, Ariti, Cono, Weisz, Giora, Witzenbichler, Bernhard, Henry, Timothy D, Kini, Annapoorna S, Stuckey, Thomas, Cohen, David J, Berger, Peter B, Iakovou, Ioannis, Dangas, George, Waksman, Ron, Antoniucci, David, Sartori, Samantha, Krucoff, Mitchell W, Hermiller, James B, Shawl, Fayaz, Gibson, C Michael, Chieffo, Alaide, Alu, Maria, Moliterno, David J, Colombo, Antonio, Pocock, Stuart

“…Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse events after percutaneous coronary intervention (PCI). Whether risk changes over time,…”
Získať plný text

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials Autor Hicks, Karen A, Mahaffey, Kenneth W, Mehran, Roxana, Nissen, Steven E, Wiviott, Stephen D, Dunn, Billy, Solomon, Scott D, Marler, John R, Teerlink, John R, Farb, Andrew, Morrow, David A, Targum, Shari L, Sila, Cathy A, Hai, Mary T Thanh, Jaff, Michael R, Joffe, Hylton V, Cutlip, Donald E, Desai, Akshay S, Lewis, Eldrin F, Gibson, C Michael, Landray, Martin J, Lincoff, A Michael, White, Christopher J, Brooks, Steven S, Rosenfield, Kenneth, Domanski, Michael J, Lansky, Alexandra J, McMurray, John J V, Tcheng, James E, Steinhubl, Steven R, Burton, Paul, Mauri, Laura, O'Connor, Christopher M, Pfeffer, Marc A, Hung, H M James, Stockbridge, Norman L, Chaitman, Bernard R, Temple, Robert J

“…This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials…”
Zistit podrobnosti o prístupe

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome Autor Mega, Jessica L, Braunwald, Eugene, Wiviott, Stephen D, Bassand, Jean-Pierre, Bhatt, Deepak L, Bode, Christoph, Burton, Paul, Cohen, Marc, Cook-Bruns, Nancy, Fox, Keith A.A, Goto, Shinya, Murphy, Sabina A, Plotnikov, Alexei N, Schneider, David, Sun, Xiang, Verheugt, Freek W.A, Gibson, C. Michael

“…In patients with acute coronary syndromes, low doses of rivaroxaban were effective in reducing the primary end point of death from cardiovascular causes,…”
Získať plný text

ST-segment elevation myocardial infarction Autor Vogel, Birgit, Claessen, Bimmer E., Arnold, Suzanne V., Chan, Danny, Cohen, David J., Giannitsis, Evangelos, Gibson, C. Michael, Goto, Shinya, Katus, Hugo A., Kerneis, Mathieu, Kimura, Takeshi, Kunadian, Vijay, Pinto, Duane S., Shiomi, Hiroki, Spertus, John A., Steg, P. Gabriel, Mehran, Roxana

“…ST-segment elevation myocardial infarction (STEMI) is the most acute manifestation of coronary artery disease and is associated with great morbidity and…”
Získať plný text

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I) Autor Michael Gibson, C, Korjian, Serge, Tricoci, Pierluigi, Daaboul, Yazan, Yee, Megan, Jain, Purva, Alexander, John H, Steg, P Gabriel, Lincoff, A Michael, Kastelein, John J P, Mehran, Roxana, D'Andrea, Denise M, Deckelbaum, Lawrence I, Merkely, Bela, Zarebinski, Maciej, Ophuis, Ton Oude, Harrington, Robert A

“…Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress…”
Zistit podrobnosti o prístupe

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Autor Steg, Philippe Gabriel, Bhatt, Deepak L, Hamm, Christian W, Stone, Gregg W, Gibson, C Michael, Mahaffey, Kenneth W, Leonardi, Sergio, Liu, Tiepu, Skerjanec, Simona, Day, Jonathan R, Iwaoka, Robert S, Stuckey, Thomas D, Gogia, Harinder S, Gruberg, Luis, French, William J, White, Harvey D, Harrington, Robert A

“…Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI) in three large,…”
Získať plný text

Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism Autor Kobayashi, Taisei, Pugliese, Steven, Sethi, Sanjum S, Parikh, Sahil A, Goldberg, Joshua, Alkhafan, Fahad, Vitarello, Clara, Rosenfield, Kenneth, Lookstein, Robert, Keeling, Brent, Klein, Andrew, Gibson, C Michael, Glassmoyer, Lauren, Khandhar, Sameer, Secemsky, Eric, Giri, Jay

“…Contemporary care patterns/outcomes in high-risk pulmonary embolism (PE) patients are unknown. This study sought to characterize the management of high-risk PE…”
Zistit podrobnosti o prístupe

Ticagrelor With or Without Aspirin After Complex PCI Autor Dangas, George, Baber, Usman, Sharma, Samin, Giustino, Gennaro, Mehta, Shamir, Cohen, David J, Angiolillo, Dominick J, Sartori, Samantha, Chandiramani, Rishi, Briguori, Carlo, Dudek, Dariusz, Escaned, Javier, Huber, Kurt, Collier, Timothy, Kornowski, Ran, Kunadian, Vijay, Kaul, Upendra, Oldroyd, Keith, Sardella, Gennaro, Shlofmitz, Richard, Witzenbichler, Bernhard, Ya-Ling, Han, Pocock, Stuart, Gibson, C Michael, Mehran, Roxana

“…Whether a regimen of ticagrelor monotherapy attenuates bleeding complications without increasing ischemic risk in patients undergoing complex percutaneous…”
Zistit podrobnosti o prístupe

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events Autor Bhatt, Deepak L, Stone, Gregg W, Mahaffey, Kenneth W, Gibson, C. Michael, Steg, P. Gabriel, Hamm, Christian W, Price, Matthew J, Leonardi, Sergio, Gallup, Dianne, Bramucci, Ezio, Radke, Peter W, Widimský, Petr, Tousek, Frantisek, Tauth, Jeffrey, Spriggs, Douglas, McLaurin, Brent T, Angiolillo, Dominick J, Généreux, Philippe, Liu, Tiepu, Prats, Jayne, Todd, Meredith, Skerjanec, Simona, White, Harvey D, Harrington, Robert A

“…This clinical trial compared two antiplatelet regimens during PCI: oral clopidogrel and intravenous cangrelor. As compared with clopidogrel, cangrelor resulted…”
Získať plný text

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention Autor Capodanno, Davide, Mehran, Roxana, Valgimigli, Marco, Baber, Usman, Windecker, Stephan, Vranckx, Pascal, Dangas, George, Rollini, Fabiana, Kimura, Takeshi, Collet, Jean-Philippe, Gibson, C Michael, Steg, Philippe Gabriel, Lopes, Renato D, Gwon, Hyeon-Cheol, Storey, Robert F, Franchi, Francesco, Bhatt, Deepak L, Serruys, Patrick W, Angiolillo, Dominick J

“…In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly known as aspirin) has been the mainstay of treatment for decades…”
Získať plný text